CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis

Histopathology

Volumn 63, Issue 6, 2013, Pages 780-787

  Morgado, José M ^a,b   Perbellini, Omar ^c   Johnson, Ryan C ^d   Teodósio, Cristina ^b,e   Matito, Almudena ^a,b   Álvarez Twose, Iván ^a,b   Bonadonna, Patrizia ^c   Zamò, Alberto ^c   Jara Acevedo, Maria ^b,e   Mayado, Andrea ^b,e   Garcia Montero, Andrés ^b,e   Mollejo, Manuela ^b,f   George, Tracy I ^d   Zanotti, Roberta ^c   Orfao, Alberto ^b,e   Escribano, Luis ^b,e   Sánchez Muñoz, Laura ^a,b  

^a Instituto de Estudios de Mastocitosis de Castilla la Mancha   (Spain)

^b Red Española de Mastocitosis   (Spain)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Bone marrow; CD30; Flow cytometry; Mastocytosis; WHO

Indexed keywords

CD30 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL; MAST CELL LEUKEMIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC MASTOCYTOSIS; WELL DIFFERENTIATED SYSTEMIC MASTOCYTOSIS;

BONE MARROW; CD30; FLOW CYTOMETRY; MASTOCYTOSIS; WHO;

ANTIGENS, CD30; BONE MARROW CELLS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84887816251     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12221     Document Type: Article

References (35)

1. Sperr WR, Escribano L, Jordan JH et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001; 25; 529-536.
2. Horny HP, Sillaber C, Menke D et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 1998; 22; 1132-1140.
3. Escribano L, Orfao A, Díaz-Agustin B et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998; 91; 731-736.
4. Teodosio C, García-Montero AC, Jara-Acevedo M et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J. Allergy Clin. Immunol. 2010; 125; 719-726, 726.e1-726.e4.
5. Valent P, Horny HP, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001; 25; 603-625.
6. Horny H-P, Metcalfe DD, Bennett JM et al. Mastocytosis. In Swerdlow SH, Campo E, Harris NL et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008; 54-63.
7. Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 2007; 37; 435-453.
8. Valent P, Horny H-P, Li CY et al. Mastocytosis (mast cell disease). In Jaffe ES, Harris NL, Stein H, Vardiman JW eds. WHO classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2001; 291-302.
9. Sotlar K, Cerny-Reiterer S, Petat-Dutter K et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod. Pathol. 2011; 24; 585-595.
10. Valent P, Sotlar K, Horny H-P. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk. Lymphoma 2011; 52; 740-744.
11. Moonim TM, Kossier T, van Der Walt J, Wilkins B, Harrison CN, Radia DH. CD30/CD123 expression in systemic mastocytosis does not correlate with aggressive disease. 54th ASH Annual Meeting and Exposition 2012; Atlanta, GA: Abstract no. 1746.
12. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299; 65-67.
13. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66; 848-858.
14. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68; 421-427.
15. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin. Immunol. 1999; 90; 157-164.
16. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85; 1-14.
17. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J. Immunol. 2004; 172; 2186-2193.
18. Sánchez-Muñoz L, Alvarez-Twose I, García-Montero AC et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod. Pathol. 2011; 24; 1157-1168.
19. Akin C, Escribano L, Nuñez R et al. Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations. J. Allergy Clin. Immunol. 2004; 113; S327.
20. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk. Res. 2001; 25; 543-551.
21. Escribano L, Navalón R, Núñez R, Díaz Agustín B, Bravo P. Immunophenotypic analysis of human mast cells by flow cytometry. Curr. Protoc. Cytom. 2001; 6; 6.6.1-6.6.18.
22. Perbellini O, Zamò A, Colarossi S et al. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders. Cytometry B Clin. Cytom. 2011; 80; 362-368.
23. Escribano L, Diaz-Agustin B, López A et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin. Cytom. 2004; 58; 1-8.
24. Maecker HT, Frey T, Nomura LE, Trotter J. Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 2004; 62A; 169-173.
25. Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108; 2366-2372.
26. Segal GH, Kjeldsberg CR, Smith GP, Perkins SL. CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am. J. Clin. Pathol. 1994; 102; 292-298.
27. Bengtsson A, Johansson C, Linder MT, Halldén G, van der Ploeg I, Scheynius A. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J. Leukoc. Biol. 1995; 58; 683-689.
28. Morgado JMT, Sánchez-Muñoz L, Teodósio CG et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod. Pathol. 2012; 25; 516-521.
29. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103; 3222-3225.
30. Alvarez-Twose I, González P, Morgado JM et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J. Clin. Oncol. 2012; 30; e126-e129.
31. Molin D, Fischer M, Xiang Z et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br. J. Haematol. 2001; 114; 616-623.
32. Younes A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 2011; 23; 587-593.
33. Skarbnik APZ, Smith MR. Brentuximab vedotin in anaplastic large cell lymphoma. Expert Opin. Biol. Ther. 2012; 12; 633-639.
34. Van de Donk NWCJ, Dhimolea E. Brentuximab vedotin. MAbs 2012; 4; 458-465.
35. Mehta A, Reddy VVB, Borate U. Anti CD-30 Antibody-drug conjugate brentuximab vedotin (ADCETRIS) may be a promising treatment option for systemic mastocytosis. 54th ASH Annual Meeting and Exposition 2012; Atlanta, GA; Abstract no. 2857.